Processa Pharmaceuticals, Inc. Proceeds from Issuance of Private Placement
Processa Pharmaceuticals, Inc. (PCSA) had Proceeds from Issuance of Private Placement of $183.30 million as of 2026-07-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfPrivatePlacement · last filed 2026-08-14
- Processa Pharmaceuticals, Inc. proceeds from issuance of private placement for the quarter ending 2021-12-31 was $173.99K.
- Processa Pharmaceuticals, Inc. proceeds from issuance of private placement for the quarter ending 2021-09-30 was $0.00.
- Processa Pharmaceuticals, Inc. proceeds from issuance of private placement for the quarter ending 2021-06-30 was $0.00.
- Processa Pharmaceuticals, Inc. proceeds from issuance of private placement for the quarter ending 2021-03-31 was $9.88M.
- Processa Pharmaceuticals, Inc. proceeds from issuance of private placement for fiscal 2021 was $10.05M.
| Period end | Proceeds from Issuance of Private Placement | Proceeds from Issuance of Private Placement 3 month | Proceeds from Issuance of Private Placement 6 month | Proceeds from Issuance of Private Placement 9 month | Proceeds from Issuance of Private Placement 12 month |
|---|---|---|---|---|---|
| 2026-07-30 | $183.30M 10-Q · filed 2026-08-14 | ||||
| 2021-12-31 | $173.99K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $173.99K derived: sum of 2 quarters · filed 2023-03-30 | $173.99K derived: sum of 3 quarters · filed 2023-03-30 | $10.05M 10-K · filed 2023-03-30 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $0.00 derived: sum of 2 quarters · filed 2022-11-08 | $9.88M 10-Q · filed 2022-11-08 | ||
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $9.88M 10-Q · filed 2022-08-11 | |||
| 2021-03-31 | $9.88M 10-Q · filed 2022-05-12 | ||||
| 2018-03-31 | $128.06K 10-Q · filed 2018-05-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |